An observational study in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 6th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 5 of the 14 other live ones, and was the 30th registered.
364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in China
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Bristol-Myers Squibb · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2014; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 362 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 59 across the 17 interventional studies, 200 across the 15 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06146660Bristol-Myers SquibbA Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | 2026-11-30 |
| NCT07557498Bristol-Myers SquibbMavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US | 2026-12-14 |
| NCT07541833Bristol-Myers SquibbEffectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) | 2026-12-31 |
| NCT06551129Bristol-Myers SquibbReal-world Patient Reported Outcomes Among Patients Treated With Camzyos | 2026-12-31 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice
The study population will consist of adults that have been diagnosed with obstructive hypertrophic cardiomyopathy (HCM) and have received treatment with mavacamten and their treating clinicians from participating community-based sites in the US.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase I: retrospective chart review
For inclusion in the study, participants must meet ALL of the following criteria:
Phase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey
Exclusion Criteria:
Participants with obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten
Drug: Mavacamten
Physicians treating patients diagnosed with obstructive hypertrophic cardiomyopathy (oHCM)
Drug: Mavacamten
According to the product label
Participant blood pressure (both systolic and diastolic)
Group 1 only
Time frame: Baseline
Date of diagnosis of hypertrophic cardiomyopathy
Group 1 only
Time frame: Baseline
Hypertrophic cardiomyopathy genetic testing results
Group 1 only
Time frame: Baseline
Family history of hypertrophic cardiomyopathy
Group 1 only
Time frame: Baseline
Family history of Sudden Cardiac Death (SCD)
Group 1 only
Time frame: Baseline
Participant comorbidities (cardiovascular and non-cardiovascular )
Group 1 only
Time frame: Baseline
Type of prior surgeries and procedures
Group 1 only. Prior surgeries and procedures include: Septal Reduction Therapy (SRT), surgeries (valve repair/placement, left atrial appendage ligation), placement of devices (Implantable Cardioverter Defibrillator (ICD), pacemaker and cardiac resynchronization therapy) or atrial fibrillation/flutter ablation
Time frame: Baseline and up to week 24
Participant New York Heart Association (NYHA) class category
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Change in participant New York Heart Association (NYHA) class from baseline
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Duration of mavacamten treatment
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Number of mavacamten dose titrations
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Type of mavacamten dose tritration
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Clinical reason for mavacamten dose titration
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Clinical reason for mavacamten treatment discontinuation
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten discontinuation if discontinued due to LVEF<50%,
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Time from mavacamten discontinuation to Left Ventricular Ejection Fraction (LVEF) recovery
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Clinical reason for temporary mavacamten treatment interuption
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Time to temporary mavacamten treatment interruption
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten interruption if the interruption was due to LVEF<50%
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Time from mavacamten treatment interruption to Left Ventricular Ejection Fraction (LVEF) recovery
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Time to mavacamten treatment resumption
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Type of hypertrophic cardiomyopathy (HCM) background therapy prescribed
Group 1 only
Time frame: Baseline, and at weeks 4, 8, 12, 24
Type of changes to hypertrophic cardiomyopathy (HCM) background therapy
Group 1 only. Type of changes include initiation, switching, discontinuation, augmentation, dose titration
Time frame: At baseline, weeks 4, 8, 12, 24
Perspectives on treatment preference, and the eligibility, onboarding and implementation of mavacamten as assessed by feedback collated through structured physician interviews
Group 2 only
Time frame: Up to week 24
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →